Current Status of PSMA-Radiotracers for Prostate Cancer: Data Analysis of Prospective Trials Listed on ClinicalTrials.gov

The recent development of dedicated prostate-specific membrane antigen (PSMA) targeted radioligands shows the potential to change and improve the diagnosis and therapy of prostate cancer. There is an increasing number of prospective trials to further establish these tracers in the clinical setting....

Descripción completa

Detalles Bibliográficos
Autores principales: Zippel, Claus, Ronski, Sarah C., Bohnet-Joschko, Sabine, Giesel, Frederik L., Kopka, Klaus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7168903/
https://www.ncbi.nlm.nih.gov/pubmed/31940969
http://dx.doi.org/10.3390/ph13010012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7168903/
https://www.ncbi.nlm.nih.gov/pubmed/31940969
http://dx.doi.org/10.3390/ph13010012

Ejemplares similares